Pharming Group N.V.
Develops and commercializes medicines for rare, debilitating, and life-threatening diseases.
PHARM | AS
Overview
Corporate Details
- ISIN(s):
- NL0010391025 (+1 more)
- LEI:
- 724500DCJ9MPG74JEH91
- Country:
- Netherlands
- Address:
- Darwinweg 24, 2333CR Leiden
- Website:
- https://www.pharming.com/
- Sector:
- Manufacturing
Description
Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company develops and commercializes an innovative portfolio of medicines to serve patients with unmet medical needs. Its portfolio includes protein replacement therapies, precision medicines, small molecules, and biologics.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-07-31 08:23 |
Pharming Group reports second quarter and first half 2025 financial results and…
|
Dutch | 669.6 KB | ||
| 2025-07-31 08:23 |
Pharming Group reports second quarter and first half 2025 financial results and…
|
English | 589.3 KB | ||
| 2025-07-31 07:16 |
Pharming Group N.V., Halfjaarlijkse financiële verslaggeving
|
English | 589.3 KB | ||
| 2025-06-24 07:35 |
Pharming Group to host webcast on findings of a new study published in Cell adv…
|
Dutch | 290.6 KB | ||
| 2025-06-24 07:35 |
Pharming Group to host webcast on findings of a new study published in Cell adv…
|
English | 260.5 KB | ||
| 2025-06-12 07:44 |
Pharming Group reports on results of the 2025 Annual General Meeting of Shareho…
|
Dutch | 182.9 KB | ||
| 2025-06-12 07:44 |
Pharming Group reports on results of the 2025 Annual General Meeting of Shareho…
|
English | 176.9 KB | ||
| 2025-05-01 06:28 |
Pharming Group announces the 2025 Annual General Meeting of Shareholders and th…
|
English | 182.9 KB | ||
| 2025-04-23 09:44 |
Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as…
|
English | 296.9 KB | ||
| 2025-04-03 07:26 |
Pharming Group N.V., Jaarlijkse financiële verslaggeving
|
English | 25.3 MB | ||
| 2025-03-04 15:29 |
Pharming Group reports on results of the 2025 Extraordinary General Meeting of …
|
Dutch | 224.7 KB | ||
| 2025-03-04 15:29 |
Pharming Group reports on results of the 2025 Extraordinary General Meeting of …
|
English | 224.4 KB | ||
| 2025-02-21 07:38 |
Pharming Technologies B.V. vergroot haar belang in Abliva AB (publ) naar 92,70 …
|
Dutch | 254.4 KB | ||
| 2025-02-21 07:38 |
Pharming Technologies B.V. increases its ownership in Abliva AB (publ) to 92.70…
|
English | 284.0 KB | ||
| 2025-02-10 07:36 |
Pharming Technologies B.V. declares unconditional and completes the recommended…
|
Dutch | 272.1 KB |
Automate Your Workflow. Get a real-time feed of all Pharming Group N.V. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Pharming Group N.V.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Pharming Group N.V. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-05-24 | D.A. Jorn | Non-Executive member | Other | 7,446 | N/A |
| 2023-03-21 | P. Sekhri | Non-Executive member | Other | 9,363 | N/A |
| 2022-10-27 | P. Sekhri | Non-Executive member | Buy | 13,013 | 12,232.22 EUR |
| 2022-10-27 | M. Pykett | Non-Executive member | Buy | 9,760 | 9,174.40 EUR |
| 2022-08-04 | P. Sekhri | Non-Executive member | Buy | 13,013 | 10,000.23 EUR |
| 2022-08-04 | S. Baert | Non-Executive member | Buy | 9,760 | 7,500.36 EUR |
| 2022-05-25 | J. van der Meijs | Non-Executive member | Buy | 9,300 | 86,490,000.00 EUR |
| 2022-05-25 | P. Sekhri | Non-Executive member | Buy | 12,398 | 9,527.62 EUR |
| 2022-05-25 | M. Pykett | Non-Executive member | Buy | 9,300 | 7,146.86 EUR |
| 2022-03-24 | S. de Vries | Non-Executive member | Buy | 318,150 | 232,249.50 EUR |
Peer Companies
